Allogene Therapeutics — Fact Sheet (September 2025)

2 slides from Allogene Therapeutics's fact sheet, September 2025

Slide 1: Who Qualifies for the RESOLUTION Trial?
Who Qualifies for the RESOLUTION Trial? Key Inclusion Criteria: Key Exclusion Criteria: • Age: 18 to <70 years. • Active systemic bacterial, fungal, or viral • Confirmed Active Autoimmune Disease: infection requiring systemic treatment. – Lupus (SLE): Active disease (e.g., SLEDAI- • Any known active
Slide 2: Introducing ALLO-329 and the RESOLUTION Trial
Introducing ALLO-329 and the The RESOLUTION Trial RESOLUTION Trial A Phase 1, first-in-human, single-arm, open-label What is CAR T-Cell Therapy? ALLO-329: A Dual-Targeted CD19/CD70 study designed to evaluate the safety, tolerability, Chimeric Antigen Receptor (CAR) T-cell therapy is a cutting-edge c